Specific interaction between tetrandrine and Quillaja saponins in promoting permeabilization of plasma membrane in human leukemic HL-60 cells

被引:20
作者
Leung, YM [1 ]
Ou, YJ [1 ]
Kwan, CY [1 ]
Loh, TT [1 ]
机构
[1] UNIV HONG KONG, FAC MED, DEPT PHYSIOL, HONG KONG, HONG KONG
来源
BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES | 1997年 / 1325卷 / 02期
关键词
saponin; tetrandrine; Ni2+; Mn2+; HL-60; cell;
D O I
10.1016/S0005-2736(97)00002-3
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Spontaneous Ni2+ entry (leak), measured as fluorescence quench in fura-2-loaded HL-60 cells at the excitation wavelength of 360 nm, was strongly inhibited by tetrandrine (TET, 100 mu M), a Ca2+ antagonist of Chinese herbal origin. Exposure of the cells for 5 min to saponins from Quillaja saponaria (QS, 30 mu g/ml), surfactants well known to permeabilize the plasma membrane by complexing with cholesterol, promoted Ni2+ entry without causing fura-2 leak-out. Unexpectedly, TET caused an immediate (within 2.5 min) augmentation of QS-promoted Ni2+ entry; and a 5-min treatment with both TET and QS resulted not only in an enhanced Ni2+ entry, but also a fura-2 leak-out. Ginseng saponins (100 mu g/ml) alone or together,with TET did not cause such a permeabilization. Permeabilization induced by 1-3 mu M digitonin, another cholesterol-complexing glycoside, could not be enhanced by TET. TET did nor affect permeabilization induced by Triton X-100 (0.01%), a detergent which non-specifically disrupts the hydrophobic interaction at the plasma membrane. TET also did not enhance Ni2+ entry triggered by ionomycin (0.35 mu M) or SK&F 96365 (20 mu M). Further, it did not augment Ni2+ entry when the plasma membrane fluidity was modulated by changes of temperature (27-47 degrees C) or treatment with 5% ethanol. This QS-promoted Ni2+ entry could not be amplified by other lipophilic Ca2+ antagonists, such as diltiazem (100 mu M) and verapamil (100 mu M). The results hence indicate that TET enhanced Ni2+ entry (or permeabilization) elicited by QS treatment, but not other perturbations of the plasma membrane. We suggest that pore formation at the plasma membrane, a consequence of QS-cholesterol interaction, can be specifically enhanced by TET. Also, a comparative study of the effects of TBT and its very close analogues, hernandezine and berbamine, reveals that the methoxyl group at the R-2 position of TET appears to be crucial in enhancing QS-promoted Ni2+ entry.
引用
收藏
页码:318 / 328
页数:11
相关论文
共 46 条
[31]   ISCOM, A NOVEL STRUCTURE FOR ANTIGENIC PRESENTATION OF MEMBRANE-PROTEINS FROM ENVELOPED VIRUSES [J].
MOREIN, B ;
SUNDQUIST, B ;
HOGLUND, S ;
DALSGAARD, K ;
OSTERHAUS, A .
NATURE, 1984, 308 (5958) :457-460
[32]   HYPOTENSIVE ACTIVITY OF TETRANDRINE IN RATS - INVESTIGATION INTO ITS MODE OF ACTION [J].
QIAN, JQ ;
THOOLEN, MJMC ;
VANMEEL, JCA ;
TIMMERMANS, PBMWM ;
VANZWIETEN, PA .
PHARMACOLOGY, 1983, 26 (04) :187-197
[33]  
RAO AV, 1995, J NUTR, V125, pS717, DOI 10.1093/jn/125.3_Suppl.717S
[34]   BLOCKING T-TYPE CALCIUM CHANNELS WITH TETRANDRINE INHIBITS STEROIDOGENESIS IN BOVINE ADRENAL GLOMERULOSA CELLS [J].
ROSSIER, MF ;
PYTHON, CP ;
CAPPONI, AM ;
SCHLEGEL, W ;
KWAN, CY ;
VALLOTTON, MB .
ENDOCRINOLOGY, 1993, 132 (03) :1035-1043
[35]   COMPARATIVE EFFECTS OF TETRANDRINE AND BERBAMINE ON PRODUCTION OF THE INFLAMMATORY CYTOKINES INTERLEUKIN-1 AND TUMOR-NECROSIS-FACTOR [J].
SEOW, WK ;
FERRANTE, A ;
SUMMORS, A ;
THONG, YH .
LIFE SCIENCES, 1992, 50 (08) :PL53-PL58
[36]   PANCREATIC ACINAR-CELL DESENSITIZATION ALTERS INSP(3), PRODUCTION AND CA2+ MOBILIZATION UNDER CONDITIONS WHERE INSP(3) RECEPTOR REMAINS INTACT [J].
SERVANT, M ;
GUILLEMETTE, G ;
MORISSET, J .
BIOCHEMICAL JOURNAL, 1995, 305 :103-110
[37]   EVIDENCE FOR MEMBRANE CHOLESTEROL AS COMMON BINDING-SITE FOR CEREOLYSIN, STREPTOLYSIN O AND SAPONIN [J].
SHANY, S ;
BERNHEIMER, AW ;
GRUSHOFF, PS ;
KIM, KS .
MOLECULAR AND CELLULAR BIOCHEMISTRY, 1974, 3 (03) :179-186
[38]   PRELIMINARY-REPORT - PROTECTION OF CYNOMOLGUS MACAQUES AGAINST SIMIAN IMMUNODEFICIENCY VIRUS BY FIXED INFECTED-CELL VACCINE [J].
STOTT, EJ ;
CHAN, WL ;
MILLS, KHG ;
PAGE, M ;
TAFFS, F ;
CRANAGE, M ;
GREENAWAY, P ;
KITCHIN, P .
LANCET, 1990, 336 (8730) :1538-1541
[39]  
STOUT MA, 1983, J PHARMACOL EXP THER, V225, P102
[40]  
TAKEMURA H, 1995, RES COMMUN MOL PATH, V90, P59